I recently posted about an organization wanting to recruit patients to do an ethnographic study for a pharmaceutical company of people living with HER2+ MBC.
The company is MacroGenics. They are conducting a Phase III clinical trial of margetumixmab. SOPHIA started in 2015 for MBC HER2+ patients. It compares that drug plus chemotherapy to Herceptin plus chemotherapy in third-line patients.